amonafide has been researched along with mitonafide in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (15.38) | 18.7374 |
| 1990's | 5 (38.46) | 18.2507 |
| 2000's | 2 (15.38) | 29.6817 |
| 2010's | 2 (15.38) | 24.3611 |
| 2020's | 2 (15.38) | 2.80 |
| Authors | Studies |
|---|---|
| Bousquet, PF; Braña, MF; Castellano, JM; Conlon, D; George, J; Maher, C; Perron, D; Qian, XD; Robinson, SP | 1 |
| Li, Y; Liu, J; Qian, X; Xu, Y; Yin, H | 1 |
| Darro, F; Dewelle, J; Dumont, P; El Yazidi, M; Gaussin, JF; Kiss, R; Lefranc, F; Mahieu, T; Mijatovic, T; Ribaucour, F; Sauvage, S; Simon, G; Tuti, J; Van Quaquebeke, E; Van Vynckt, F | 1 |
| Hardebeck, LK; Hudson, GA; Johnson, CA; Jolley, EA; Lewis, M; Ren, Y; Znosko, BM | 1 |
| Huang, RZ; Jiang, H; Liang, GB; Qin, JT; Wang, HL; Wang, HS; Wei, JH; Zhang, Y | 1 |
| Camacho Sánchez, MA; Torres Suárez, AI | 1 |
| Hsiang, YH; Jiang, JB; Liu, LF | 1 |
| Braña, MF; Cañete, M; Stockert, JC | 1 |
| Camacho, MA; Gil, ME; Obregón, MM; Ruz, V; Torres, AI | 1 |
| Bousquet, P; Braña, MF; Castellano, JM; Emling, F; Keilhauer, G; Morán, M; Pérez de Vega, MJ; Qian, XD; Romerdahl, CR; Schlick, E | 1 |
| Braña, MF; Castellano, JM; Emling, F; Klebe, G; Kluge, M; Morán, M; Schlick, E; Walker, N | 1 |
| Byczek-Wyrostek, A; Kasprzycki, P; Strama, K; Tomczyk, MD; Walczak, KZ; Wawszków, M | 1 |
| Chen, XM; Huang, R; Liang, SM; Liu, SQ; Lu, L; Song, LH; Wang, HL; Wang, Q; Wei, JH; Zhang, Y; Zhou, JY | 1 |
13 other study(ies) available for amonafide and mitonafide
| Article | Year |
|---|---|
Chromophore-modified bis-naphthalimides: synthesis and antitumor activity of bis-dibenz[de,h]isoquinoline-1,3-diones.
Topics: 1-Naphthylamine; Amides; Animals; Antineoplastic Agents; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA, Superhelical; Humans; Isoquinolines; Mice; Tumor Cells, Cultured | 1997 |
Novel N-oxide of naphthalimides as prodrug leads against hypoxic solid tumor: synthesis and biological evaluation.
Topics: Antineoplastic Agents; Cell Hypoxia; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; Naphthalimides; Neoplasms; Oxides; Prodrugs; Structure-Activity Relationship | 2007 |
2,2,2-Trichloro-N-({2-[2-(dimethylamino)ethyl]-1,3-dioxo-2,3-dihydro-1H-benzo[de]isoquinolin- 5-yl}carbamoyl)acetamide (UNBS3157), a novel nonhematotoxic naphthalimide derivative with potent antitumor activity.
Topics: Acetamides; Adenine; Animals; Antineoplastic Agents; Apoptosis; Autophagy; Camptothecin; Cell Line, Tumor; Cellular Senescence; Deoxycytidine; Drug Screening Assays, Antitumor; Erythrocyte Count; Female; Gemcitabine; Humans; Imides; Irinotecan; Isoquinolines; Leukocyte Count; Maximum Tolerated Dose; Mice; Naphthalimides; Neoplasm Transplantation; Organophosphonates; Platelet Count; Structure-Activity Relationship; Topoisomerase I Inhibitors; Urea | 2007 |
Effect of intercalator substituent and nucleotide sequence on the stability of DNA- and RNA-naphthalimide complexes.
Topics: Antineoplastic Agents; Base Sequence; DNA; Intercalating Agents; Molecular Sequence Data; Naphthalimides; Nucleic Acid Conformation; Nucleic Acid Denaturation; Nucleotides; RNA; Structure-Activity Relationship; Temperature; Thermodynamics | 2015 |
Design, synthesis and antitumor evaluation of new 1,8-naphthalimide derivatives targeting nuclear DNA.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; DNA Damage; Drug Design; Humans; Mice, Nude; Naphthalimides; Neoplasms | 2021 |
Studies about the oral bioavailability of mitonafide and 2HCl amonafide, two new cytotoxic molecules.
Topics: Adenine; Antineoplastic Agents; Biological Availability; Hydrogen-Ion Concentration; Imides; Intercalating Agents; Isoquinolines; Naphthalimides; Organophosphonates; Solubility | 1992 |
Topoisomerase II-mediated DNA cleavage by amonafide and its structural analogs.
Topics: Adenine; Animals; Cell Line; DNA Damage; DNA Topoisomerases, Type II; DNA, Viral; Haplorhini; Imides; In Vitro Techniques; Intercalating Agents; Isoquinolines; Naphthalimides; Nucleic Acid Conformation; Organophosphonates; Simian virus 40; Structure-Activity Relationship; Topoisomerase II Inhibitors | 1989 |
[Antineoplastic drugs used as fluorochromes].
Topics: Adenine; Animals; Antineoplastic Agents; Chemical Phenomena; Chemistry; Chickens; DNA; Fluorescent Dyes; Imides; Isoquinolines; Naphthalimides; Organophosphonates | 1982 |
Qualitative and quantitative determination of two new antitumor agents from 1-8 naphthalimides in tablets. Validation of a high performance liquid chromatography method.
Topics: Adenine; Antineoplastic Agents; Chromatography, High Pressure Liquid; Excipients; Imides; Isoquinolines; Naphthalimides; Organophosphonates; Regression Analysis; Tablets | 1994 |
Bis-naphthalimides: a new class of antitumor agents.
Topics: Adenine; Animals; Antineoplastic Agents; Humans; Imides; Intercalating Agents; Isoquinolines; Mice; Naphthalenes; Naphthalimides; Neoplasms, Experimental; Organophosphonates; Structure-Activity Relationship; Tumor Cells, Cultured | 1993 |
Synthesis, structure and antitumor activity of new benz[d,e]isoquinoline-1,3-diones.
Topics: Adenine; Animals; Antineoplastic Agents; Chemical Phenomena; Chemistry, Physical; Crystallography, X-Ray; Drug Screening Assays, Antitumor; Imides; Isoquinolines; Leukemia L1210; Mice; Mice, Inbred DBA; Models, Molecular; Molecular Conformation; Naphthalimides; Organophosphonates; Tumor Cells, Cultured | 1995 |
Anticancer Activity and Topoisomerase II Inhibition of Naphthalimides with ω-Hydroxylalkylamine Side-Chains of Different Lengths.
Topics: Adenine; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; DNA Topoisomerases, Type II; Drug Screening Assays, Antitumor; Humans; Molecular Structure; Naphthalimides; Organophosphonates; Structure-Activity Relationship; Topoisomerase II Inhibitors | 2019 |
Design, synthesis, and antitumor evaluation of morpholine substituted bisnaphthalimides as DNA targeting agents.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; DNA; Drug Screening Assays, Antitumor; Humans; Molecular Structure; Morpholines; Structure-Activity Relationship | 2023 |